Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Mosunetuzumab + Lenalidomide for Lymphoma
Recruiting1 awardPhase 2
New Haven, Connecticut
This trial is testing a new treatment for lymphoma that involves using mosunetuzumab alone for four cycles, followed by an assessment of response. If the patient responds well, they will continue treatment with mosunetuzumab. If the patient does not respond well, they will receive mosunetuzumab with lenalidomide augmentation during the next four cycles.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service